Abstract
Major finding: A screen of FDA-approved agents identified tigecycline as a selective inhibitor of AML.
Mechanism: AML cells are sensitive to inhibition of mitochondrial translation by tigecycline.
Impact: Tigecycline may be effective in AML alone or in combination with standard chemotherapy.
This content is only available via PDF.
©2011 American Association for Cancer Research.
2011
